Vision Solutions Technologies, Inc. to Present at Medtech Insight and Windhover Information's ''Investment In Innovation (In3) WEST'' Conference, February 23-24, 2006, Irvine, CA.

IRVINE, Calif. -- Vision Solutions Technologies has announced that it will be presenting on Thursday at 5:00 p.m. at Medtech Insight and Windhover Information's "Investment In Innovation (In3) WEST: A Preview of Early-Stage Medical Technology Companies" Conference, February 23-24, 2006 at the Hyatt Regency Irvine in Irvine, California.

Vision Solutions Technologies, Inc., (VST), Rockville, Maryland, was founded by Dr. Alan N. Glazier. Dr. Glazier developed an implantable ophthalmic device, LiquiLens(TM), to treat vision correction associated with Age related Macular Degeneration (AMD). This market represents one of the largest and rapidly growing markets in ophthalmology with significant unmet medical needs. With an exceptional management team in place, world renowned board of ophthalmologists as scientific advisors, a strong intellectual property position and a best-in-class product with few competitors, VST is poised to become a major market force in the AMD market space.

LiquiLens(TM) is a fluid-filled intraocular lens (IOL) that functions as a high powered magnifier for near vision in patients with macular disease of the retina. Two independent, optical analyses have verified the LiquiLens(TM) design. Prototyping has confirmed the results of the optical analyses. In addition, the pivotal patent covering this technology was issued by the USPTO in February, 2005.

AMD is the leading cause of sub-acute vision and blindness in people over age 55. Sub-acute vision device companies address a huge market that includes major portions of the population suffering from AMD, diabetic retinopathy, and cataracts. Worldwide, about 135 million people have sub-acute vision. As the population continues to age, the number of those with sub-acute vision is expected to grow, along with the incidence of these eye diseases. As the Baby Boomer population continues to mature, and the population of the over-60 age group grows, the incidence of AMD will soar, driving the demand for solutions such as LiquiLens(TM) that correct the condition sufficiently to improve quality of life.

There are a number of pharmaceuticals in development or recently approved that are intended to arrest the progression of the disease but no products that significantly improve vision or quality of life for the recipient. LiquiLens(TM) Intraocular lens for optical treatment of age related macular degeneration is synergistic with all of these products, and will provide the perfect adjunctive treatment.

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. In3 WEST is Medtech Insight's 20th investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at [phone] or [phone] toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.